Understanding Patient Experiences with Chronic Hepatitis B Virus (cHBV) and its Treatments

Author(s)

DiBenedetti D1, Mansfield C1, Myers K1, Satram S2, Reyes C2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Vir Biotechnology, San Francisco, CA, USA

OBJECTIVES : Despite advances in the treatment of cHBV, unmet needs remain, including how patients perceive the value of a “functional cure” (lifelong control of the virus after a finite duration of therapy). We conducted qualitative interviews to better understand the impact of cHBV and its treatments on patients’ lives and the perceived value of a functional cure.

METHODS : Individual telephone interviews were conducted during March-April 2020. Participants were 18+ years with cHBV for ≥6 months, no other viral coinfections, and either current or past experience with interferon and/or nucleoside analogue or were treatment naive.

RESULTS : Of the 28 participants, 23 were treatment-experienced and 5 were treatment-naïve. The sample was racially/ethnically diverse (50% non-white), had a mean age of 47.5 years, and 54% were male. All participants reported impacts of cHBV on their lives with emotional impacts (including stigma and discrimination) most frequently reported (53%), followed by physical impacts (50%), dietary and lifestyle impacts (32%), and social impacts (29%). Although many treatment-experienced patients had difficulty differentiating the impacts of cHBV treatment from the disease itself, nearly all (21/23) reported negative impacts associated with treatment. When asked for the attributes of an “ideal treatment”, participants spontaneously reported a long-acting formulation with less frequent administration (61%), a cure (32%), an oral formulation (29%), or a convenient treatment that did not require travel (18%). More than half (n=15) described a functional cure as a partial, temporary, and/or incomplete cure, something that “worked” to some extent, was perhaps associated with fewer or better controlled symptoms, but was not a full or permanent cure. Most patients found the notion of a functional cure appealing once defined for them.

CONCLUSIONS : Patients reported persistent unmet needs with cHBV treatment, including dosing frequency, formulation, and convenience. The majority of patients value treatments that provide a functional cure.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)

Code

PIN72

Topic

Patient-Centered Research

Topic Subcategory

Patient Behavior and Incentives, Patient-reported Outcomes & Quality of Life Outcomes, Stated Preference & Patient Satisfaction

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×